← Leaderboards
Glenn J Lesser
Wake Forest University
$30,601,947
Attributed
$53,622,556
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,622,556 · 5
By mechanism
UG1$52,170,737 · 1
U01$659,543 · 1
UH2$457,460 · 1
M01$334,816 · 2
Top collaborators
- Kathryn Elizabeth Weaver16 shared
- Emily Van Meter Dressler4 shared
- Madan M Kwatra1 shared
Most similar at Wake Forest University
Same institution · by research overlap
- Mark O. Lively$1,524,042
- Mark C Willingham$1,166,451
- Andrew D Pearlman$0
- Alan J Townsend$3,980,665
- Michael J Thomas$928,612
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseClinical ResearchCommunity Clinical Oncology ProgramCancer CareCommunitiesCare DeliveryResearch PersonnelMentorsCancer ControlTrainingNext GenerationResourcesAreaSiteInvestigationNeurocognitivePostdoctoral FellowForestCollectionEarly TreatmentMalignant NeoplasmsCancer TherapyCardiovascular SystemNci Center For Cancer Research
Grant awards (31)
Wake Forest NCORP Research Base$3,850,852
UG1 · FY2025 · CA · contact PI
Wake Forest NCORP Research Base$4,147,567
UG1 · FY2024 · CA · contact PI
Wake Forest NCORP Research Base$217,552
UG1 · FY2024 · CA · contact PI
Wake Forest NCORP Research Base$3,738,633
UG1 · FY2023 · CA · contact PI
Wake Forest NCORP Research Base$3,481,649
UG1 · FY2022 · CA · contact PI
Wake Forest NCORP Research Base$1,574,957
UG1 · FY2022 · CA · contact PI
Clinical Studies NCORP Boot Camp Program for Early-Career Investigators$387,500
UG1 · FY2022 · CA · contact PI
Wake Forest NCORP Research Base$4,106,807
UG1 · FY2021 · CA · contact PI
Wake Forest NCORP Research Base$1,620,862
UG1 · FY2021 · CA · contact PI
Developing and Implementing a Culturally Appropriate Non-Opioid Pain Coping Skills Training Intervention for Spanish-Speaking Hispanic/Latinx Patients with Cancer Pain$581,183
UG1 · FY2021 · CA · contact PI
Wake Forest NCORP Research Base$4,855,150
UG1 · FY2020 · CA · contact PI
Wake Forest NCORP Research Base$1,286,843
UG1 · FY2020 · CA · contact PI
Wake Forest NCORP Research Base$4,237,731
UG1 · FY2019 · CA · contact PI
Wake Forest NCORP Research Base$924,073
UG1 · FY2019 · CA · contact PI
Wake Forest NCORP Research Base$3,106,081
UG1 · FY2018 · CA · contact PI
Wake Forest NCORP Research Base$3,481,450
UG1 · FY2017 · CA · contact PI
Wake Forest NCORP Research Base$189,075
UG1 · FY2017 · CA · contact PI
Wake Forest NCORP Research Base$2,896,475
UG1 · FY2016 · CA · contact PI
Wake Forest NCORP Research Base$189,075
UG1 · FY2016 · CA · contact PI
Wake Forest NCORP Research Base$3,690,620
UG1 · FY2015 · CA · contact PI
Evaluation of AZD9291 in Glioblastoma patients with activated EGFR$457,460
UH2 · FY2015 · TR
Wake Forest NCORP Research Base$3,606,602
UG1 · FY2014 · CA · contact PI
New Approaches to Brain Tumor Therapy, NABTT CNS$133,650
U01 · FY2008 · CA · contact PI
New Approaches to Brain Tumor Therapy, NABTT CNS$132,324
U01 · FY2007 · CA · contact PI
New Approaches to Brain Tumor Therapy, NABTT CNS$132,308
U01 · FY2006 · CA · contact PI
New Approaches to Brain Tumor Therapy, NABTT CNS$131,546
U01 · FY2005 · CA
New Approaches to Brain Tumor Therapy, NABTT CNS$129,715
U01 · FY2004 · CA
PHASE I EVALUATION OF PHENYLBUTYRATE IN PT W/ REFRACTORY MALIGNANT G$143,176
M01 · FY2002 · RR
PHASE II REPETITIVE IV DOSES OF RSR13 TO PT RECEIVING CRANIAL RADIATI$143,176
M01 · FY2002 · RR
PHASE I EVALUATION OF PHENYLBUTYRATE IN PT W/ REFRACTORY MALIGNANT G$24,232
M01 · FY2000 · RR
PHASE II REPETITIVE IV DOSES OF RSR13 TO PT RECEIVING CRANIAL RADIATI$24,232
M01 · FY2000 · RR